Press Room MediaRoom Toujeo® reduced risk of severe low blood sugar compared to insulin glargine 100 Units/mL and insulin detemir Wed, 14 Feb 2018 07:20:00 -0500 Sanofi Delivers 2017 Business EPS in line with Guidance Wed, 07 Feb 2018 07:38:00 -0500 Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Mon, 08 Jan 2018 18:05:00 -0500 Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma High and durable response rate in disease without any FDA-approved therapies Wed, 13 Dec 2017 12:27:00 -0500 FDA Approves Sanofi's Admelog® (insulin lispro injection) * First FDA-approved follow-on mealtime insulin Mon, 11 Dec 2017 14:40:00 -0500